Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:41 UTC |
---|
HMDB ID | HMDB0014638 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Zidovudine |
---|
Description | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] |
---|
Structure | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 |
---|
Synonyms | Value | Source |
---|
Azidothymidine | ChEBI | AZT | ChEBI | Retrovir | ChEBI | Zidovudin | ChEBI | Zidovudinum | ChEBI | 3'-Azido-3'-deoxythymidine | Kegg | 3'-Azido-2',3'-dideoxythymidine | HMDB | AZT antiviral | HMDB | BWA 509u | HMDB | AZT (antiviral) | HMDB | 3' Azido 3' deoxythymidine | HMDB | Antiviral azt | HMDB | BW a509U | HMDB | 3' Azido 2',3' dideoxythymidine | HMDB | AZT, antiviral | HMDB | BWA-509u | HMDB | BWA509u | HMDB |
|
---|
Chemical Formula | C10H13N5O4 |
---|
Average Molecular Weight | 267.2413 |
---|
Monoisotopic Molecular Weight | 267.096753929 |
---|
IUPAC Name | 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione |
---|
Traditional Name | zidovudine |
---|
CAS Registry Number | 30516-87-1 |
---|
SMILES | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O |
---|
InChI Identifier | InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 |
---|
InChI Key | HBOMLICNUCNMMY-XLPZGREQSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrimidine 2',3'-dideoxyribonucleosides. Pyrimidine 2',3'-dideoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at positions 2 and 3. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Pyrimidine nucleosides |
---|
Sub Class | Pyrimidine 2',3'-dideoxyribonucleosides |
---|
Direct Parent | Pyrimidine 2',3'-dideoxyribonucleosides |
---|
Alternative Parents | |
---|
Substituents | - Pyrimidine 2',3'-dideoxyribonucleoside
- Pyrimidone
- Hydroxypyrimidine
- Hydropyrimidine
- Pyrimidine
- Tetrahydrofuran
- Heteroaromatic compound
- Azo imide
- Azo compound
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organic zwitterion
- Alcohol
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 106 - 112 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 16.3 g/L | Not Available | LogP | 0.05 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Zidovudine,1TMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C)O2)C(=O)[NH]C1=O | 2410.0 | Semi standard non polar | 33892256 | Zidovudine,1TMS,isomer #2 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)N([Si](C)(C)C)C1=O | 2478.0 | Semi standard non polar | 33892256 | Zidovudine,2TMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 2469.3 | Semi standard non polar | 33892256 | Zidovudine,2TMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 2578.6 | Standard non polar | 33892256 | Zidovudine,2TMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 3831.4 | Standard polar | 33892256 | Zidovudine,1TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)[NH]C1=O | 2656.2 | Semi standard non polar | 33892256 | Zidovudine,1TBDMS,isomer #2 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2707.6 | Semi standard non polar | 33892256 | Zidovudine,2TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2927.9 | Semi standard non polar | 33892256 | Zidovudine,2TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 3016.9 | Standard non polar | 33892256 | Zidovudine,2TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 3832.0 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Zidovudine GC-MS (Non-derivatized) - 70eV, Positive | splash10-014i-9220000000-d55aacb79cb345dd1f0a | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Zidovudine GC-MS (1 TMS) - 70eV, Positive | splash10-0100-9631000000-1d566216a7cf9f0cc760 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Zidovudine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , negative-QTOF | splash10-00di-0190000000-46ee7eb3034a9b20706d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , negative-QTOF | splash10-00di-0790000000-19916045eff2f2277d60 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , negative-QTOF | splash10-0fk9-0900000000-836aff54cb90ce573db4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , negative-QTOF | splash10-00di-0900000000-cb1ef888d872056bce56 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , negative-QTOF | splash10-00di-0900000000-97660ea43493fa2fa991 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , negative-QTOF | splash10-05fr-0900000000-407e81a32dbf5eb07134 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , positive-QTOF | splash10-004i-0900000000-743290b40f399a527da5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , positive-QTOF | splash10-004i-0900000000-667b9ae1f4c499b8cef6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , positive-QTOF | splash10-004i-0900000000-c6bf89700e58ad9aff83 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , positive-QTOF | splash10-004i-1900000000-b644d0eec4449bae7675 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , positive-QTOF | splash10-01t9-2900000000-d794028d708aa5c5d04f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine LC-ESI-QFT , positive-QTOF | splash10-03gi-5900000000-b2b0a6ddec7e2e91e8c4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 15V, Negative-QTOF | splash10-00di-0190000000-7866a2ae697bd4bdd557 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 30V, Negative-QTOF | splash10-00di-0790000000-7a80e5d85a6e3caa70dc | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 90V, Positive-QTOF | splash10-03gi-4900000000-f20d571f80dacd82de5d | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 75V, Positive-QTOF | splash10-01t9-2900000000-8d394bc55d4ea0b1cb90 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 15V, Positive-QTOF | splash10-004i-0900000000-bd6dbcfb91438fe39bc1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 30V, Positive-QTOF | splash10-004i-0900000000-661e1e92b9a14d53eda3 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zidovudine 60V, Positive-QTOF | splash10-004i-0900000000-c1e03c652eda06f4c392 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zidovudine 10V, Positive-QTOF | splash10-014i-0090000000-65bdc875b481997f35b0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zidovudine 20V, Positive-QTOF | splash10-03di-0090000000-cbe4e5e680eed587e220 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zidovudine 40V, Positive-QTOF | splash10-007c-9200000000-9732b6de02e7378e613c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zidovudine 10V, Negative-QTOF | splash10-014i-2090000000-d30081dd79d918431d63 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zidovudine 20V, Negative-QTOF | splash10-014i-4290000000-42d4b65040e25cf691f5 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zidovudine 40V, Negative-QTOF | splash10-0006-9500000000-50cff13af2772ff9bd1e | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
General References | - Mitsuya H, Yarchoan R, Broder S: Molecular targets for AIDS therapy. Science. 1990 Sep 28;249(4976):1533-44. [PubMed:1699273 ]
- Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S: 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100. [PubMed:2413459 ]
- Yarchoan R, Mitsuya H, Broder S: AIDS therapies. Sci Am. 1988 Oct;259(4):110-9. [PubMed:3072667 ]
- De Clercq E: HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 1994 Jan 20;47(2):155-69. [PubMed:7508227 ]
- Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173-80. [PubMed:7935654 ]
- Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ: Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33. [PubMed:12920168 ]
|
---|